Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update

ICOTYDE™ (icotrokinra) approved by FDA in March for moderate-to-severe plaque psoriasis, triggering a $50 million ...

Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration

Opt-out election makes Protagonist eligible for $200 million upon exercise and an additional $200 million upon FDA ...
Fierce Biotech

Protagonist opts for $475M in Takeda payouts instead of splitting US rusfertide profits

After mulling its options for the past few months, Protagonist Therapeutics has decided to pocket $475 million from Takeda ...
The Indianapolis Star

Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

NDA for rusfertide submitted to the US Food and Drug Administration (FDA), with potential approval and launch this year Company expects to opt-out of the 50:50 profit and loss sharing arrangement for ...
Monthly Prescribing Reference

Hepcidin Mimetic Rusfertide Gets Priority Review for Polycythemia Vera

Rusfertide significantly improves hematocrit control and reduces the mean number of phlebotomies in patients who are phlebotomy-dependent despite standard care. The Food and Drug Administration (FDA) ...
Medscape

Hematocrit, Phlebotomy Benefits Seen With Rusfertide in PV

ORLANDO, Fla. — Rusfertide, a weekly self-injected peptide, maintained control of hematocrit levels and reductions in phlebotomy requirements through 52 weeks in patients with polycythemia vera (PV), ...
AZ Central

Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

NEWARK, CALIFORNIA / ACCESS Newswire / February 25, 2026 / Protagonist Therapeutics (Nasdaq:PTGX) (“Protagonist” or “the Company”) today reported financial results for the fourth quarter and full year ...